MECHELEN, BELGIUM and HARLOW, UK--(Marketwire - October 04, 2010) -
· Galapagos' affiliate, Argenta, to
develop candidate drugs based on multiple oncology targets
· Largest deal so far for Argenta
· Initial phase includes research
funding and success-based milestones over five years
· Option to further extend to 15
oncology target programs
Galapagos NV (Euronext: GLPG)
announced today that its affiliate, Argenta Discovery 2009 Limited, has
into a drug discovery service agreement with Janssen Pharmaceutica
(Janssen), aimed at delivering novel cancer drug candidates. Argenta
provide medicinal chemistry and biology for a number of Janssen
targets. The total contract value for Galapagos for the initial phase
collaboration could exceed EUR33.5 M over a five-year period
achievement of certain milestones.
This fully integrated drug discovery service agreement calls for
perform hit-to-lead and lead optimization for a number of Janssen
targets, and also activities up to pre-clinical candidate selection.
retains the option to extend the services beyond the initial set of
to a total of 15 targets.
"We are seeing an increased demand for longer term, integrated deals
services business, which access a variety of our drug discovery
with Argenta's strong track record of delivering on integrated drug
programs, we are well positioned to meet this growing need," said Onno
Stolpe, CEO of Galapagos.
Argenta's contract research, which includes expertise in medicinal
computer-aided drug discovery,in vitro biology, analytics, in
pharmacokinetics, pharmacology and world-leading respiratory models,
strong reputation for scientific excellence. Argenta was acquired by
in February 2010 and employs over 140 people in the UK with its main
in Harlow. More info at: www.argentadiscovery.com
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology
specialized in the discovery and development of small molecule and
therapies with novel modes-of-action. The Company is progressing one
largest pipelines in biotech, with six clinical and over 50 small
discovery/pre-clinical programs. Through risk/reward-sharing alliances
GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and
Galapagos is eligible to receive up to EUR3.3 billion in downstream
plus royalties. Following the recent acquisition of the Zagreb research
the Galapagos Group now has over 800 employees and operates facilities in
countries, with global headquarters in Mechelen, Belgium. More
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
This release may contain forward-looking statements, including,
limitation, statements containing the words "believes,"
"expects," "intends," "plans," "seeks," "estimates," "may," "will,"
"stands to," and "continues," as well as similar expressions. Such
looking statements may involve known and unknown risks, uncertainties and
factors which might cause the actual results, financial condition,
or achievements of Galapagos, or industry results, to be materially
from any historic or future results, financial conditions,
achievements expressed or implied by such forward-looking statements.
these uncertainties, the reader is advised not to place any undue
such forward-looking statements. These forward-looking statements speak
of the date of publication of this document. Galapagos expressly
obligation to update any such forward-looking statements in this
reflect any change in its expectations with regard thereto or any
events, conditions or circumstances on which any such statement is based,
required by law or regulation.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Galapagos NV via Thomson Reuters ONE